综述:GLP-1受体激动剂在消化内科实践中的角色演变
本文为叙述性综述,汇总至2025年的临床试验、队列研究与指南更新,评估GLP-1受体激动剂在肥胖及相关消化系统疾病中的疗效、安全性与临床影响。综述指出其可带来显著且持久的减重效果,已获批用于脂肪性肝病并显示组织学与生化获益,可能降低部分消化道肿瘤发生率,但常见胃肠道不良反应可能影响围内镜管理。
要点
- GLP-1受体激动剂可显著且持久减重,并改善肥胖相关消化系统结局。
- 已获批用于脂肪性肝病,并显示组织学与生化获益。
- 常见恶心、呕吐、腹泻、便秘及胃排空延迟,可能影响围内镜管理。
核心结论
- GLP-1受体激动剂是肥胖及多种相关消化系统疾病的关键治疗,消化内科医生在优化使用、管理不良反应和协调多学科照护方面具有独特优势。
研究设计与样本
- 叙述性综述,汇总至2025年的近期临床试验、队列研究和指南更新,覆盖脂肪性肝病、胃食管反流、炎症性肠病、短肠综合征及肥胖相关癌症等消化系统疾病。
主要发现
- GLP-1受体激动剂可诱导显著且持久的体重下降,并改善肥胖相关消化系统结局。
- 在脂肪性肝病中已获批,并显示组织学与生化获益。
- 证据提示可降低几种消化道肿瘤的发生率。
- 最常见不良事件包括恶心、呕吐、腹泻、便秘和胃排空延迟,可能影响围内镜管理。
- 停药率仍较高,但可通过仔细滴定和专科监督加以缓解。
关键数值与推荐
- 肥胖影响超过40%的美国人群,并导致多种疾病结局更差。
- GLP-1受体激动剂在胃肠道分布有密集受体。
- 已获批用于脂肪性肝病并显示组织学与生化获益。
临床怎么用
- 消化内科医生可优化GLP-1受体激动剂的使用并管理其不良反应。
- 需关注胃排空延迟等不良事件对围内镜管理的影响。
- 通过仔细滴定和专科监督可缓解较高的停药率。
- 应协调多学科照护,确保安全有效地整合入实践。
局限性
- 本文为叙述性综述,非系统评价或荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity affects over 40% of the US population and contributes to worse outcomes in a variety of diseases and disorders. Glucagon-like peptide-1 receptor agonists have drawn attention for their impact on obesity. With a dense population of receptors throughout the gastrointestinal tract, it is critical to understand the way that glucagon-like peptide-1 receptor agonists impact gastrointestinal diseases and disorders. AIMS: To evaluate the expanding role of glucagon-like peptide-1 receptor agonists in the management of obesity and gastrointestinal disease, with a focus on therapeutic applications, impact on gastrointestinal cancers, safety profile, and implications for gastroenterology practice. METHODS: We conducted a narrative review of recent clinical trials, cohort studies, and guideline updates through 2025. Evidence was synthesised on efficacy, safety, and clinical implications across gastrointestinal disorders including steatotic liver disease, gastroesophageal reflux, inflammatory bowel disease, short bowel syndrome, and obesity-associated cancers. RESULTS: Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes. They are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits. Evidence suggests a reduced incidence of several gastrointestinal cancers. The most common adverse events include nausea, vomiting, diarrhoea, constipation, and delayed gastric emptying, which may affect peri-endoscopic management. Discontinuation rates remain substantial but can be mitigated by careful titration and specialist oversight. CONCLUSIONS: Glucagon-like peptide-1 receptor agonists are a critical therapy for obesity and several related gastrointestinal conditions. Gastroenterologists are uniquely positioned to optimize their use, manage adverse events, coordinate multidisciplinary care, and ensure safe and effective integration into practice.
引用
- Pomenti S, Gerber A, Katzka D, et al. Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice. Aliment Pharmacol Ther. 2025. PMID: 41215723. doi:10.1111/apt.70450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。